NCCR AntiResist aims to match the rapid evolutionary pace of antimicrobial resistance (AMR) with a new paradigm in antibiotic discovery targeting in vivo pathogen behaviour.
Antimicrobial resistance (AMR), the evolved ability of bacteria and other microbes to evade antibiotic treatment, is now a global threat, and after thirty years of stagnation in the development of new antibiotics, we are faced with the very near prospect of a post-antibiotic era. While new antibiotics may provide a temporary reprieve, AntiResist plays a pivotal role in addressing this innovation gap for good. With a fundamental shift towards in vivo antibiotic research, we are providing the standard for continual novel antibiotic discovery to keep pace with AMR evolution for generations to come.
About NCCR AntiResist
The National Center of Competence in Research (NCCR) AntiResist is a Swiss research consortium funded by the Swiss National Science Foundation (SNSF), which aims to tackle the urgent global imperative of antimicrobial resistance (AMR), one of the top ten threats to global health. AntiResist is a diverse panel of experts in the fields of clinical research, infection biology, and engineering, which aims at transforming the research and development of new antibiotics and antimicrobial strategies by building human tissue-based infection models to screen and discover new antibiotics.
Based at the Biozentrum of the University of Basel, NCCR AntiResist oversees 30 research groups across Switzerland and Israel, and is developing close collaborations with the private sector involved in antibiotic R&D. Current project partnerships with industry include Roche, Spexis, BioVersys and Basilea.
Diversity & Inclusion
Collaboration and Diversity in Research
We are committed to upholding values which support and enhance our multi-disciplinary approach, and recognise the importance of diverse perspectives, expertise, and backgrounds in tackling complex challenges related to AMR.